Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLKL | Q8NB16 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1063186 | 0.87 | ALDH1A1 (0.43) | MLKLCYP1A2CYP2C19KDM4EMAPT | |
| SCHEMBL210355 | 0.85 | MLKL (0.50) | MLKLCYP1A2CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL3560549 | 0.81 | TAS1R3 (0.41) | CYP1A2CYP2C19KDM4ECA1CA2 | |
| SCHEMBL211176 | 0.81 | APP (0.46) | KDM4EMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL1065500 | 0.80 | HDAC1 (0.55) | MEN1KMT2AHDAC6 | |
| SCHEMBL1066308 | 0.80 | HDAC1 (0.42) | CYP1A2CYP2C19MAPTMEN1KMT2A | |
| SCHEMBL210928 | 0.78 | EGLN1 (0.45) | MLKLCYP1A2EGLN1TDP1TSHR | |
| SCHEMBL1664788 | 0.77 | CHEK2 (0.68) | CYP1A2CYP2C19KDM4EMAPTMEN1 | |
| SCHEMBL209291 | 0.76 | STK33 (0.42) | KDM4EMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL1460061 | 0.75 | KDM4E (0.58) | CYP1A2CYP2C19CYP3A4CYP2C9CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868204-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7838520-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2010-11-23 | — | — | US | disclosed |
| US-7595343-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2009-09-29 | — | — | US | disclosed |
| US-20060058298-A1 | Inhibitors of histone deacetylase | METHYLGENE, INC. | 2006-03-16 | — | — | US | disclosed |
| US-20050288282-A1 | Inhibitors of histone deacetylase | METHYLGENE, INC. | 2005-12-29 | — | — | US | disclosed |
| EP-1590340-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2005-11-02 | — | — | EP | disclosed |
| US-6897220-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2005-05-24 | — | — | US | disclosed |
| WO-2004069823-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2004-08-19 | — | — | WO | disclosed |
| US-20040142953-A1 | Inhibitors of histone deacetylase | METHYLGENE, INC. | 2004-07-22 | — | — | US | disclosed |
| EP-1429765-A2 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2004-06-23 | — | — | EP | disclosed |
| US-20040106599-A1 | Inhibitors of histone deacetylase | 92229129 QUEBEC INC. (CA) | 2004-06-03 | — | — | US | disclosed |
| WO-2004005513-A2 | METHODS FOR SPECIFICALLY INHIBITING HISTONE DEACETYLASE-7 AND 8 | METHYLGENE, INC. (CA) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003024448-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288282-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | MLKL 2017/4885CYP1A2 4430/4885CYP2C19 4798/4885 |
| US-20040106599-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | MLKL 2017/4885CYP1A2 4430/4885CYP2C19 4798/4885 |
| US-20060058298-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | MLKL 2017/4885CYP1A2 4430/4885CYP2C19 4798/4885 |
| US-20040142953-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | MLKL 2017/4885CYP1A2 4430/4885CYP2C19 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.